Cidara Therapeutics, Inc.
CDTX
$22.36
-$0.64-2.78%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 302.00K | 973.00K | 2.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 302.00K | 973.00K | 2.76M |
| Cost of Revenue | 46.87M | 12.43M | 6.66M | 5.92M | 8.01M |
| Gross Profit | -46.87M | -12.43M | -6.36M | -4.95M | -5.25M |
| SG&A Expenses | 7.31M | 4.97M | 4.75M | 3.60M | 3.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.18M | 17.39M | 11.40M | 9.52M | 11.46M |
| Operating Income | -54.18M | -17.39M | -11.10M | -8.54M | -8.70M |
| Income Before Tax | -52.37M | -15.54M | -94.21M | -8.18M | -8.17M |
| Income Tax Expenses | -- | -- | -- | -- | 7.00K |
| Earnings from Continuing Operations | -52.37M | -15.54M | -94.21M | -8.18M | -8.18M |
| Earnings from Discontinued Operations | 62.00K | -450.00K | 3.00M | -2.15M | 4.97M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.31M | -15.99M | -91.21M | -10.33M | -3.21M |
| EBIT | -54.18M | -17.39M | -11.10M | -8.54M | -8.70M |
| EBITDA | -54.14M | -17.35M | -11.06M | -8.51M | -8.67M |
| EPS Basic | -5.38 | -2.45 | -19.99 | -2.28 | -0.71 |
| Normalized Basic EPS | -3.36 | -1.49 | -1.28 | -1.13 | -1.13 |
| EPS Diluted | -5.38 | -2.45 | -19.99 | -2.28 | -0.71 |
| Normalized Diluted EPS | -3.36 | -1.49 | -1.28 | -1.13 | -1.13 |
| Average Basic Shares Outstanding | 9.73M | 6.53M | 4.56M | 4.54M | 4.53M |
| Average Diluted Shares Outstanding | 9.73M | 6.53M | 4.56M | 4.54M | 4.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
